[go: up one dir, main page]

PL1667991T3 - Pochodne chinazoliny jako inhibitory kinazy tyrozynowej - Google Patents

Pochodne chinazoliny jako inhibitory kinazy tyrozynowej

Info

Publication number
PL1667991T3
PL1667991T3 PL04768469T PL04768469T PL1667991T3 PL 1667991 T3 PL1667991 T3 PL 1667991T3 PL 04768469 T PL04768469 T PL 04768469T PL 04768469 T PL04768469 T PL 04768469T PL 1667991 T3 PL1667991 T3 PL 1667991T3
Authority
PL
Poland
Prior art keywords
tyrosine kinase
kinase inhibitors
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
PL04768469T
Other languages
English (en)
Inventor
Laurent Francois Andre Hennequin
Christopher Thomas Halsall
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34315440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1667991(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0321620.7A external-priority patent/GB0321620D0/en
Priority claimed from GB0406163A external-priority patent/GB0406163D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL1667991T3 publication Critical patent/PL1667991T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL04768469T 2003-09-16 2004-09-13 Pochodne chinazoliny jako inhibitory kinazy tyrozynowej PL1667991T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0321620.7A GB0321620D0 (en) 2003-09-16 2003-09-16 Quinazoline derivatives
GB0406163A GB0406163D0 (en) 2004-03-19 2004-03-19 Quinazoline derivatives
PCT/GB2004/003923 WO2005026150A1 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
EP04768469A EP1667991B1 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
PL1667991T3 true PL1667991T3 (pl) 2008-12-31

Family

ID=34315440

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04768469T PL1667991T3 (pl) 2003-09-16 2004-09-13 Pochodne chinazoliny jako inhibitory kinazy tyrozynowej

Country Status (24)

Country Link
US (2) US7569577B2 (pl)
EP (1) EP1667991B1 (pl)
JP (1) JP4795952B2 (pl)
AR (1) AR045663A1 (pl)
AT (1) ATE395346T1 (pl)
AU (1) AU2004272348B2 (pl)
BR (1) BRPI0414489A8 (pl)
CA (1) CA2538884C (pl)
CO (1) CO5690594A2 (pl)
CY (1) CY1108186T1 (pl)
DE (1) DE602004013806D1 (pl)
DK (1) DK1667991T3 (pl)
ES (1) ES2305844T3 (pl)
HR (1) HRP20080329T3 (pl)
IL (1) IL174261A0 (pl)
MX (1) MXPA06002964A (pl)
NO (1) NO20061322L (pl)
PL (1) PL1667991T3 (pl)
PT (1) PT1667991E (pl)
RU (1) RU2378268C2 (pl)
SI (1) SI1667991T1 (pl)
TW (1) TW200519104A (pl)
UA (1) UA84167C2 (pl)
WO (1) WO2005026150A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532524A (en) * 2001-11-03 2007-02-23 Astrazeneca Ab Quinazoline derivatives as antitumor agents
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
US20070032508A1 (en) * 2003-09-16 2007-02-08 Bradbury Robert H Quinazoline derivatives as tyrosine kinase inhibitors
DE602004022180D1 (de) * 2003-09-16 2009-09-03 Astrazeneca Ab Chinazolinderivate
EP1664030A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
US8017321B2 (en) * 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
ES2677562T3 (es) * 2004-05-27 2018-08-03 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
WO2005118572A1 (en) * 2004-06-04 2005-12-15 Astrazeneca Ab Quinazoline derivatives as erbb receptor tyrosine kinases
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
JP2008516973A (ja) 2004-10-15 2008-05-22 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1838712B8 (en) * 2004-12-14 2011-10-12 AstraZeneca AB Pyrazolopyrimidine compounds as antitumor agents
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
EP1861094A4 (en) * 2005-03-11 2014-06-11 Univ Colorado HISTONDEACETYLASE INHIBITORS SENSITIZE CANCER CELLS FOR EPIDERMAL GROWTH FACTOR INHIBITORS
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
CA2619037A1 (en) * 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
WO2007034144A1 (en) * 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
JP2009508917A (ja) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
ATE443053T1 (de) * 2005-12-02 2009-10-15 Astrazeneca Ab Als inhibitoren von erbb-tyrosinkinase verwendete chinazoleinderivate
JP2009517450A (ja) * 2005-12-02 2009-04-30 アストラゼネカ アクチボラグ チロシンキナーゼ阻害薬としての４−アニリノ置換キナゾリン誘導体
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CN101535279B (zh) 2006-09-11 2015-05-20 柯瑞斯公司 含锌结合基的喹唑啉基egfr抑制剂
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
CN102452988B (zh) 2010-10-27 2016-01-27 中国科学院化学研究所 一种喹唑啉衍生物及其制备方法
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092529A1 (es) * 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
EP2958911B1 (en) 2013-02-21 2017-10-18 GlaxoSmithKline Intellectual Property Development Limited Quinazolines as kinase inhibitors
WO2018094225A1 (en) 2016-11-17 2018-05-24 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812257A (en) * 1972-04-07 1974-05-21 Sumitomo Chemical Co Uricosuric agent
US3971783A (en) * 1973-03-07 1976-07-27 Pfizer Inc. 4-Aminoquinazoline derivatives as cardiac stimulants
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
KR910006138B1 (ko) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
US5411963A (en) 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU2010792A (en) 1991-05-20 1992-12-30 Rhone-Poulenc Rorer International (Holdings) Inc. Aromatic oligomeric compounds useful as mimics of bioactive macromolecules
US5441963A (en) * 1991-12-20 1995-08-15 Merrell Dow Pharmaceuticals Potentiation of NMDA antagonists
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5395846A (en) 1993-06-25 1995-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors
US5614627A (en) 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996033977A1 (en) 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9515975D0 (en) * 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
US6127366A (en) * 1995-11-22 2000-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997018813A1 (en) 1995-11-22 1997-05-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9604311D0 (en) * 1996-02-29 1996-05-01 Merck & Co Inc Inhibitors of farnesyl-protein transferase
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP2000504336A (ja) * 1996-02-02 2000-04-11 ゼネカ・リミテッド 薬学製剤として有用なヘテロ環式化合物
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
CN1923818A (zh) 1996-04-12 2007-03-07 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
ES2384551T3 (es) 1997-03-05 2012-07-06 Sugen, Inc. Formulaciones para agentes farmacéuticos hidrófobos
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
DE19816983A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel
US6200976B1 (en) * 1998-04-17 2001-03-13 Boehringer Ingelheim Pharma Kg Antithrombotic quinoxazolines
WO2000009481A1 (en) 1998-08-11 2000-02-24 Takeda Chemical Industries, Ltd. Cyclic amide compounds, process for producing the same, intermediates thereof and herbicides
JP2002523403A (ja) 1998-08-21 2002-07-30 パーカー ヒューズ インスティテュート キナゾリン誘導体
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CZ303681B6 (cs) 1998-09-29 2013-03-06 Wyeth Holdings Corporation Substituované deriváty 3-kyanochinolinu jako inhibitory proteintyrosinkináz
EP1117653B1 (en) 1998-10-01 2003-02-05 AstraZeneca AB Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
DK1119567T3 (da) 1998-10-08 2005-07-25 Astrazeneca Ab Quinazolinderivater
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
PT1131304E (pt) * 1998-11-19 2003-04-30 Warner Lambert Co N-¬4-(3-cloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quinazolin-6-il|-acrilamida um inibidor irreversivel de tirosino quinases
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CZ306810B6 (cs) 1999-02-10 2017-07-19 Astrazeneca Ab Použití chinazolinového derivátu jako inhibitoru angiogeneze
DE19908567A1 (de) 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
KR20020068261A (ko) 1999-02-27 2002-08-27 베링거 잉겔하임 파르마 카게 티로신 키나제에 의해 매개되는 신호 변환에 대한 억제효과를 갖는 4-아미노-퀴나졸린 및 퀴놀린 유도체
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
SK287010B6 (sk) 1999-06-21 2009-09-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyklické heterocyklické zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
AU780787B2 (en) 1999-09-17 2005-04-14 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
KR20020032608A (ko) 1999-09-21 2002-05-03 다비드 에 질레스 퀴나졸린 화합물 및 이를 함유하는 제약 조성물
HK1046686A1 (zh) 1999-09-21 2003-01-24 Astrazeneca Ab 喹唑啉衍生物及其作為藥物的應用
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
SI1676845T1 (sl) * 1999-11-05 2008-10-31 Astrazeneca Ab Novi kinazolinski derivati
DE60121931T2 (de) 2000-04-07 2007-03-01 Astrazeneca Ab Chinazolinverbindungen
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012870A (es) 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
DE10040527A1 (de) 2000-08-18 2002-02-28 Boehringer Ingelheim Pharma Chinazoline und Verfahren zu ihrer Herstellung
CN100347169C (zh) 2000-08-21 2007-11-07 阿斯特拉曾尼卡有限公司 喹唑啉衍生物
US6617329B2 (en) * 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
DE10042060A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6740651B2 (en) * 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042062A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung
DE10042061A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6656946B2 (en) * 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
EP1320529B1 (en) 2000-09-21 2006-05-24 Smithkline Beecham Plc Quinoline derivatives as antibacterials
US6849625B2 (en) 2000-10-13 2005-02-01 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
US20040063733A1 (en) 2000-10-25 2004-04-01 Lambert Christine Marie Paul Quinazoline derivatives
DE10206505A1 (de) 2002-02-16 2003-08-28 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
AU2002210714A1 (en) 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
ATE369894T1 (de) 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
WO2002062767A1 (en) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
CN1264824C (zh) 2001-02-21 2006-07-19 三菱制药株式会社 喹唑啉衍生物
PL364625A1 (pl) 2001-02-23 2004-12-13 Merck & Co, Inc. N-podstawieni, niearylowi heterocykliczni antagoniści NMDA/NR2B
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
AU2002250394A1 (en) 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
WO2002092578A1 (en) * 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002094790A1 (en) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
CA2349044A1 (en) 2001-05-28 2002-11-28 Optenia, Inc. Method of polarisation compensation in grating-and phasar-based devices by using overlayer deposited on the compensating region to modify local slab waveguide birefringence
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
EP1578722A4 (en) 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
NZ532524A (en) * 2001-11-03 2007-02-23 Astrazeneca Ab Quinazoline derivatives as antitumor agents
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
GB0128109D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
AU2002339687A1 (en) 2001-12-12 2003-06-23 Pfizer Products Inc. Quinazoline derivatives for the treatement of abnormal cell growth
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
EA009300B1 (ru) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) * 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10217689A1 (de) 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
EP1505966A4 (en) 2002-05-10 2006-08-30 Bristol Myers Squibb Co 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER
US20030225079A1 (en) * 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
EP1510221A4 (en) * 2002-06-03 2009-04-29 Mitsubishi Tanabe Pharma Corp MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
KR100942073B1 (ko) 2002-08-23 2010-02-12 기린 홀딩스 가부시키가이샤 ＴＧＦ β 저해 활성을 갖는 화합물 및 그것을 포함하여 이루어지는 의약 조성물
WO2004064718A2 (en) 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
GB0309009D0 (en) 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
EP1660479A1 (en) * 2003-07-29 2006-05-31 Astrazeneca AB Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
US20070032508A1 (en) * 2003-09-16 2007-02-08 Bradbury Robert H Quinazoline derivatives as tyrosine kinase inhibitors
EP1664030A1 (en) 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
DE602004022180D1 (de) 2003-09-16 2009-09-03 Astrazeneca Ab Chinazolinderivate
DE602004004553T2 (de) 2003-09-19 2007-10-25 Astrazeneca Ab Chinazolinderivate
US20070037837A1 (en) * 2003-09-19 2007-02-15 Hennequin Laurent Francois A Quinazoline derivatives
WO2005030757A1 (en) 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
US7894637B2 (en) * 2004-05-21 2011-02-22 Asahi Kasei Corporation Device, program, and method for classifying behavior content of an object person
WO2005118572A1 (en) * 2004-06-04 2005-12-15 Astrazeneca Ab Quinazoline derivatives as erbb receptor tyrosine kinases
EP1838712B8 (en) 2004-12-14 2011-10-12 AstraZeneca AB Pyrazolopyrimidine compounds as antitumor agents
US8735410B2 (en) 2005-02-26 2014-05-27 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0504475D0 (en) 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0504474D0 (en) 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
WO2007034144A1 (en) 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
JP2009508917A (ja) 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
JP2009517450A (ja) 2005-12-02 2009-04-30 アストラゼネカ アクチボラグ チロシンキナーゼ阻害薬としての４−アニリノ置換キナゾリン誘導体
ATE443053T1 (de) 2005-12-02 2009-10-15 Astrazeneca Ab Als inhibitoren von erbb-tyrosinkinase verwendete chinazoleinderivate

Also Published As

Publication number Publication date
UA84167C2 (ru) 2008-09-25
EP1667991A1 (en) 2006-06-14
JP4795952B2 (ja) 2011-10-19
HRP20080329T3 (en) 2008-08-31
SI1667991T1 (sl) 2008-10-31
DE602004013806D1 (en) 2008-06-26
CO5690594A2 (es) 2006-10-31
MXPA06002964A (es) 2006-06-14
US20070043009A1 (en) 2007-02-22
WO2005026150A1 (en) 2005-03-24
US7569577B2 (en) 2009-08-04
BRPI0414489A (pt) 2006-11-14
ES2305844T3 (es) 2008-11-01
RU2006112599A (ru) 2007-11-10
NO20061322L (no) 2006-06-15
DK1667991T3 (da) 2008-08-18
BRPI0414489A8 (pt) 2019-01-15
AR045663A1 (es) 2005-11-02
US20090312343A1 (en) 2009-12-17
CA2538884C (en) 2010-09-21
PT1667991E (pt) 2008-07-14
CY1108186T1 (el) 2014-02-12
RU2378268C2 (ru) 2010-01-10
TW200519104A (en) 2005-06-16
EP1667991B1 (en) 2008-05-14
AU2004272348B2 (en) 2008-09-04
IL174261A0 (en) 2006-08-01
CA2538884A1 (en) 2005-03-24
ATE395346T1 (de) 2008-05-15
AU2004272348A1 (en) 2005-03-24
HK1091480A1 (en) 2007-01-19
JP2007505872A (ja) 2007-03-15

Similar Documents

Publication Publication Date Title
IL174261A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
IL174258A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
AU2003299651A8 (en) Tyrosine kinase inhibitors
EP1581539A4 (en) NEW TYROSINE KINASE HEMMER
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
IL174948A0 (en) Imidazopyrazine tyrosine kinase inhibitors
IL180806A0 (en) Imidazopyrazine as tyrosine kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
AU2003233455A1 (en) Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors
IL173593A0 (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
AU2003275282A8 (en) Novel tyrosine kinase inhibitors
IL177007A0 (en) 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
PL376255A1 (pl) Pochodne chinazoliny jako inhibitory kinaz tyrozynowych Src
SI1660090T1 (sl) Kinazolinski analogi kot inhibitorji receptorjev tirozin kinaze
ZA200608998B (en) Imidazole derivatives as tyrosine kinase inhibitors
EP1651209A4 (en) TYROSINE KINASE INHIBITORS
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
IS8386A (is) Kínasólínafleiður sem týrósínkínasatálmar
GB0201384D0 (en) Tyrosine kinase inhibitors
SI1684750T1 (sl) aminoariloksazolne spojine kot inhibitorji tirozin kinaze